Zymeworks
Most recent annual filing: 2026-03-02
- Zanidatamab NMPA China decision2026Zanidatamab NMPA China decision, 2026, major
- ZW191 interim2026ZW191 interim, 2026, notable
- ZW209 IND filing2026ZW209 IND filing, 2026, notable
- ZW1528 IND filing2026ZW1528 IND filing, 2026, notable
- Zanidatamab HERIZON-GEA-01 interim3Q 2026Zanidatamab HERIZON-GEA-01 interim, 3Q 2026, material
- Zanidatamab Ziihera PDUFA dateAug 25, 2026Zanidatamab Ziihera PDUFA date, Aug 25, 2026, thesis-defining
- Theravance Biopharma YUPELRI strategic reviewAug 25, 2026Theravance Biopharma YUPELRI strategic review, Aug 25, 2026, routine
- YUPELRI/TRELEGY ELLIPTA milestone corporate update1Q 2027YUPELRI/TRELEGY ELLIPTA milestone corporate update, 1Q 2027, routine
- Pasritamig J&J Ph3 startDec 2027Pasritamig J&J Ph3 start, Dec 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (11 active programs)
pasritamig
JNJ-78278343ZW191
Protein Target: FRα, folate receptor alpha
ZW251
Protein Target: GPC3, glypican 3
ZW220
ZW209
Protein Target: DLL3, Delta-like ligand 3
ZW1528
Technology platforms
Azymetric
Multispecific antibody platform enabling bispecific and trispecific antibody development; produces both ADC backbones and multispecific therapeutics including TriTCE and ProTECT combinations; focus areas: oncology, inflammation, autoimmune disease
Targets: HER2
EFECT
Antibody effector function modulation platform consisting of Fc region modifications enabling selective enhancement or suppression of immune effector function; used in oncology, inflammation, and autoimmune therapeutics
ProTECT
Conditionally active antibody technology that masks an antibody arm outside the tumor to improve selectivity and minimize off-target toxicities; activated by tumor-specific proteases; focus: oncology tumor microenvironment
Pan-RAS ADC
Proprietary Pan-RAS antibody-drug conjugate (ADC) platform; company evaluating formation of a separate dedicated entity with third-party capital to advance multiple product candidates into clinical studies.
Targets: RAS
Biotech Distilled coverage (2)
- 2026-08-07 UPDATE: Zymeworks (ZYME) - The Runway Guidance Just Disappeared 🔒 Paid
- 2026-07-09 Zymeworks Inc. (ZYME) — Scientific Deep Dive for Zanidatamab (Ziihera®), ZW191, and the Royalty-Aggregation Pipeline 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.